Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Pershing Square, Valeant to appear in court on insider trading suit settlement

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/03/2018 | 07:16am CEST
Ackman, CEO of Pershing Square Capital, speaks at the WSJ Digital Conference in Laguna Beach

(Reuters) - A U.S. court on Tuesday asked Valeant Pharmaceuticals International Inc (>> Valeant Pharmaceuticals Intl Inc) and activist investor Bill Ackman's Pershing Square (>> Pershing Square Holdings) to appear for a hearing to discuss the proposed settlement in an insider trading lawsuit.

(Reuters) - A U.S. court on Tuesday asked Valeant Pharmaceuticals International Inc (>> Valeant Pharmaceuticals Intl Inc) and activist investor Bill Ackman's Pershing Square (>> Pershing Square Holdings) to appear for a hearing to discuss the proposed settlement in an insider trading lawsuit.

The hearing, set for Jan. 16, comes after Pershing Square and Valeant last week decided to pay $290 million to settle the lawsuit that accused them of insider trading before bidding for Allergan Plc (>> Allergan plc) in 2014.

The lawsuit was filed on behalf of investors who sold Allergan shares in the two months before Pershing Square Capital Management and Valeant made an unsolicited $51 billion bid for Allergan.

The court has "substantial questions regarding whether the settlement amount is reasonable and fair," according to documents filed in the U.S. District Court, Central District of California.

"Today's order is a mandated step in the settlement process," a Valeant spokeswoman said in an email to Reuters. "We believe the settlement is fair, reasonable and adequate, and we look forward to explaining our position to the Court."

Pershing Square could not be reached for comment outside regular business hours.

(Reporting by Abinaya Vijayaraghavan in Bengaluru; Editing by Amrutha Gayathri)

Stocks mentioned in the article
ChangeLast1st jan.
PERSHING SQUARE HOLDINGS 0.66% 15.2 Delayed Quote.11.19%
VALEANT PHARMACEUTICALS INTL INC -1.95% 30.2 Delayed Quote.17.56%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALLERGAN PLC
07/12ALLERGAN : An Application for the Trademark "VESSILA" Has Been Filed by Allergan
AQ
07/12Novartis Becomes Latest Player to Exit Antibiotic, Antiviral Research
DJ
07/12ALLERGAN : Expands REFRESH Portfolio With New REFRESH REPAIR Lubricant Eye Drops
AQ
07/11ALLERGAN : Forbion raises EUR 270M, surpassing target for fourth fund
AQ
07/10ALLERGAN : Expands REFRESH® Portfolio With New REFRESH® REPAIR Lubricant Eye Dro..
PR
07/06ALLERGAN : Study in Chronic Migraine Receives Migraine Research Award at the Ame..
AQ
07/05ALLERGAN : An Application for the Trademark "ANDRODERM" Has Been Filed by Allerg..
AQ
06/29ALLERGAN : Eases Manual Data Entry and Contract Management Pains with Pramatas B..
AQ
06/28ALLERGAN : An Application for the Trademark "ANDRODERM" Has Been Filed by Allerg..
AQ
06/28ALLERGAN : Study in Chronic Migraine Receives Migraine Research Award at the Ame..
PU
More news
News from SeekingAlpha
07/16CVS responds to Trump Administration's request for info on now to lower drug .. 
07/16ALLERGAN : Crucial Period Ahead For Company As Activist Pressure Mounts 
07/12Establishment Labs Prepares For U.S. IPO 
07/12Drug prices still marching upward - Bloomberg 
07/12CEF THW : Undervalued And 10%+ Yield 
Financials ($)
Sales 2018 15 306 M
EBIT 2018 7 381 M
Net income 2018 -1 152 M
Debt 2018 23 173 M
Yield 2018 1,55%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,44x
EV / Sales 2019 5,12x
Capitalization 60 065 M
Chart ALLERGAN PLC
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 207 $
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC7.38%60 065
JOHNSON & JOHNSON-9.87%337 763
PFIZER3.62%219 534
NOVARTIS-3.93%201 464
ROCHE HOLDING LTD.-5.60%200 973
MERCK AND COMPANY11.76%169 193